Association of Chemotherapy Response Score with Multidrug Resistance 1 and CA125 ELIMination Rate Constant K in Patients with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

Association of Chemotherapy Response Score with Multidrug Resistance 1 and CA125 ELIMination Rate Constant K in Patients with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy

Published:2023-06-30 Issue:1.2 Volume:70 Page:29-37
ISSN:0023-5679
Container-title:The Kurume Medical Journal
language:en
Short-container-title:Kurume Med. J.

Author:

MATSUKUMA KEN¹,NISHIO SHIN¹,TASAKI SHINGO¹,PARK JONGMYUNG¹,NASU HIROKI¹,YOSHIMITSU TERUYUKI¹,TASAKI KAZUTO¹,KATSUDA TAKAHIRO¹,TERADA ATSUMU¹,TSUDA NAOTAKE¹,SANADA SAKIKO²,USHIJIMA KIMIO¹

Affiliation:

1. Department of Obstetrics and Gynecology, Kurume University School of Medicine

2. Department of Pathology, Kurume University School of Medicine

Publisher

Kurume Medical Journal

Link

https://www.jstage.jst.go.jp/article/kurumemedj/70/1.2/70_MS7012004/_pdf

Reference34 articles.

1. 1. Reid BM, Permuth JB, and Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017; 14:9-32.

2. 2. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019 2019; 17:896-909.

3. 3. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T et al. Neoadjuvant chemotherapy or primary surgery in stage III C or IV ovarian cancer. N Engl J Med 2010; 363:943-953.

4. 4. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomized, controlled, non-inferiority trial. Lancet 2015; 386:249-257.

5. 5. Onda T, Satoh T, Ogawa G, Saito T, Kasamatsu T et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial. Eur J Cancer 2020; 130:114-125.